Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TopHill: Neoadjuvant Immunochemotherapy vs Standard Therapy for Locally Advanced Oral Squamous Cell Carcinoma
NCT06258811Phase 3Recruiting
- Start
- Feb 2024
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tislelizumab in oral squamous cell carcinoma (OSCC) (2 arms). Primary endpoints: Event-Free Survival at 2 years and Overall Survival at 2 years. Started Feb 2024; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT06258811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06258811.